Cargando…

Novel Selective IDO1 Inhibitors with Isoxazolo[5,4-d]pyrimidin-4(5H)-one Scaffold

Indoleamine 2,3-dioxygenase 1 (IDO1) is a promising target in immunomodulation of several pathological conditions, especially cancers. Here we present the synthesis of a series of IDO1 inhibitors with the novel isoxazolo[5,4-d]pyrimidin-4(5H)-one scaffold. A focused library was prepared using a 6- o...

Descripción completa

Detalles Bibliográficos
Autores principales: Dolšak, Ana, Bratkovič, Tomaž, Mlinarič, Larisa, Ogorevc, Eva, Švajger, Urban, Gobec, Stanislav, Sova, Matej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8001472/
https://www.ncbi.nlm.nih.gov/pubmed/33804161
http://dx.doi.org/10.3390/ph14030265
_version_ 1783671238108905472
author Dolšak, Ana
Bratkovič, Tomaž
Mlinarič, Larisa
Ogorevc, Eva
Švajger, Urban
Gobec, Stanislav
Sova, Matej
author_facet Dolšak, Ana
Bratkovič, Tomaž
Mlinarič, Larisa
Ogorevc, Eva
Švajger, Urban
Gobec, Stanislav
Sova, Matej
author_sort Dolšak, Ana
collection PubMed
description Indoleamine 2,3-dioxygenase 1 (IDO1) is a promising target in immunomodulation of several pathological conditions, especially cancers. Here we present the synthesis of a series of IDO1 inhibitors with the novel isoxazolo[5,4-d]pyrimidin-4(5H)-one scaffold. A focused library was prepared using a 6- or 7-step synthetic procedure to allow a systematic investigation of the structure-activity relationships of the described scaffold. Chemistry-driven modifications lead us to the discovery of our best-in-class inhibitors possessing p-trifluoromethyl (23), p-cyclohexyl (32), or p-methoxycarbonyl (20, 39) substituted aniline moieties with IC(50) values in the low micromolar range. In addition to hIDO1, compounds were tested for their inhibition of indoleamine 2,3-dioxygenase 2 and tryptophan dioxygenase, and found to be selective for hIDO1. Our results thus demonstrate a successful study on IDO1-selective isoxazolo[5,4-d]pyrimidin-4(5H)-one inhibitors, defining promising chemical probes with a novel scaffold for further development of potent small-molecule immunomodulators.
format Online
Article
Text
id pubmed-8001472
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80014722021-03-28 Novel Selective IDO1 Inhibitors with Isoxazolo[5,4-d]pyrimidin-4(5H)-one Scaffold Dolšak, Ana Bratkovič, Tomaž Mlinarič, Larisa Ogorevc, Eva Švajger, Urban Gobec, Stanislav Sova, Matej Pharmaceuticals (Basel) Article Indoleamine 2,3-dioxygenase 1 (IDO1) is a promising target in immunomodulation of several pathological conditions, especially cancers. Here we present the synthesis of a series of IDO1 inhibitors with the novel isoxazolo[5,4-d]pyrimidin-4(5H)-one scaffold. A focused library was prepared using a 6- or 7-step synthetic procedure to allow a systematic investigation of the structure-activity relationships of the described scaffold. Chemistry-driven modifications lead us to the discovery of our best-in-class inhibitors possessing p-trifluoromethyl (23), p-cyclohexyl (32), or p-methoxycarbonyl (20, 39) substituted aniline moieties with IC(50) values in the low micromolar range. In addition to hIDO1, compounds were tested for their inhibition of indoleamine 2,3-dioxygenase 2 and tryptophan dioxygenase, and found to be selective for hIDO1. Our results thus demonstrate a successful study on IDO1-selective isoxazolo[5,4-d]pyrimidin-4(5H)-one inhibitors, defining promising chemical probes with a novel scaffold for further development of potent small-molecule immunomodulators. MDPI 2021-03-15 /pmc/articles/PMC8001472/ /pubmed/33804161 http://dx.doi.org/10.3390/ph14030265 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ).
spellingShingle Article
Dolšak, Ana
Bratkovič, Tomaž
Mlinarič, Larisa
Ogorevc, Eva
Švajger, Urban
Gobec, Stanislav
Sova, Matej
Novel Selective IDO1 Inhibitors with Isoxazolo[5,4-d]pyrimidin-4(5H)-one Scaffold
title Novel Selective IDO1 Inhibitors with Isoxazolo[5,4-d]pyrimidin-4(5H)-one Scaffold
title_full Novel Selective IDO1 Inhibitors with Isoxazolo[5,4-d]pyrimidin-4(5H)-one Scaffold
title_fullStr Novel Selective IDO1 Inhibitors with Isoxazolo[5,4-d]pyrimidin-4(5H)-one Scaffold
title_full_unstemmed Novel Selective IDO1 Inhibitors with Isoxazolo[5,4-d]pyrimidin-4(5H)-one Scaffold
title_short Novel Selective IDO1 Inhibitors with Isoxazolo[5,4-d]pyrimidin-4(5H)-one Scaffold
title_sort novel selective ido1 inhibitors with isoxazolo[5,4-d]pyrimidin-4(5h)-one scaffold
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8001472/
https://www.ncbi.nlm.nih.gov/pubmed/33804161
http://dx.doi.org/10.3390/ph14030265
work_keys_str_mv AT dolsakana novelselectiveido1inhibitorswithisoxazolo54dpyrimidin45honescaffold
AT bratkovictomaz novelselectiveido1inhibitorswithisoxazolo54dpyrimidin45honescaffold
AT mlinariclarisa novelselectiveido1inhibitorswithisoxazolo54dpyrimidin45honescaffold
AT ogorevceva novelselectiveido1inhibitorswithisoxazolo54dpyrimidin45honescaffold
AT svajgerurban novelselectiveido1inhibitorswithisoxazolo54dpyrimidin45honescaffold
AT gobecstanislav novelselectiveido1inhibitorswithisoxazolo54dpyrimidin45honescaffold
AT sovamatej novelselectiveido1inhibitorswithisoxazolo54dpyrimidin45honescaffold